Initiates Coverage on Ampio Pharmaceuticals (NYSE:AMPE) initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Rating) in a research note issued to investors on Friday. The brokerage issued a sell rating on the stock.

AMPE opened at $0.44 on Friday. The stock has a market cap of $99.37 million, a PE ratio of -4.37 and a beta of 1.54. The company has a 50-day simple moving average of $0.46. Ampio Pharmaceuticals has a 12 month low of $0.39 and a 12 month high of $2.01.

Ampio Pharmaceuticals Company Profile (Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.

Further Reading

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.